OCUGEN, INC. Cash and Restricted Cash
OCUGEN, INC. (OCGN) had Cash and Restricted Cash of $100.37 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $100.37M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32.17M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.89M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32.88M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $100.37M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $32.17M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $18.89M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $32.88M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $27.32M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $38.11M 10-Q · filed 2026-05-08 | |
| 2024-12-31 | $58.82M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $39.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $16.00M 10-Q · filed 2025-08-04 | |
| 2024-03-31 | $26.38M 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $39.46M 10-K · filed 2026-03-04 | |
| 2023-09-30 | $53.48M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $70.58M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $68.26M 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $77.56M 10-K · filed 2025-03-05 | |
| 2022-09-30 | $101.60M 10-K · filed 2024-04-16 | |
| 2022-06-30 | $115.00M 10-K · filed 2024-04-16 | |
| 2022-03-31 | $129.92M 10-K · filed 2024-04-16 | |
| 2021-12-31 | $95.11M 10-K · filed 2024-04-16 | |
| 2021-09-30 | $107.50M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $115.79M 10-Q · filed 2022-08-05 | |
| 2021-03-31 | $44.94M 10-Q · filed 2022-05-06 | |
| 2020-12-31 | $24.19M 10-K · filed 2023-02-28 | $24.19M 10-K · filed 2021-03-19 |
| 2020-09-30 | $19.26M 10-Q · filed 2021-11-09 | $19.26M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $15.12M 10-Q · filed 2021-08-06 | $15.12M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $3.34M 10-Q · filed 2021-05-07 | $3.34M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $7.59M 10-K · filed 2022-02-28 | $7.60M 10-K · filed 2020-03-27 |
| 2019-09-30 | $15.45M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $829.27K 10-Q · filed 2020-08-14 | $2.79M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $459.34K 10-Q · filed 2020-05-08 | $7.51M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $1.78M 10-K · filed 2022-02-28 | $1.78M 8-K/A · filed 2019-10-07 |
| 2018-09-30 | $2.63M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $6.42M 8-K/A · filed 2019-10-07 | $8.91M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $15.64M 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $6.30M 10-K · filed 2020-03-27 | $7.22M 10-Q · filed 2018-05-10 |
| 2017-03-31 | $16.51M 10-Q · filed 2018-05-10 | |
| 2016-12-31 | $32.05M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |